#What is Alto Neuroscience's Recent Development?
Alto Neuroscience, focusing on neuropsychiatric disorders, has successfully raised $120 million. This funding comes from a range of institutional and accredited investors and aims to advance ALTO-207, their innovative treatment targeting resistant forms of depression. This novel combination therapy merges pramipexole, a dopamine receptor agonist, with ondansetron, enhancing the antidepressant effects specifically for patients who haven’t seen benefits from standard treatments.
The recent funding round, prominently led by Commodore Capital, sets the stage for Phase 2b and Phase 3 clinical trials. Should these studies yield positive results, Alto anticipates potentially submitting a New Drug Application. Other notable participants in this funding round include Dellora Investments, Driehaus Capital Management, and several healthcare investment firms.
#How Will the Funding Impact Clinical Trials?
The details indicate that the PIPE will encompass both common stock and pre-funded warrants, with the transaction poised to conclude shortly. The backing from this prominent group of investors showcases their confidence in Alto’s focused strategy in precision neuroscience and the promising future of ALTO-207 as a breakthrough treatment for patients experiencing significant unmet medical needs.
As Alto Neuroscience gears up for its clinical trials, they also reported their operations for 2025, showcasing a cash balance of $177 million. This amount is expected to sustain operations through to 2028 while supporting several critical clinical milestones. They plan to initiate Phase 2b testing by the first half of 2026, leading to a Phase 3 study beginning in early 2027.
#What are the Financial Highlights from Alto's Report?
The company also anticipates topline data near the end of the first quarter of 2026 from a Phase 2 proof-of-concept trial focused on ALTO-101, addressing cognitive impairments associated with schizophrenia. For the fiscal year 2025, Alto reported R&D expenses exceeding $45 million, with additional general and administrative expenses totaling $20.7 million. The net loss reported for the year stands at approximately $63 million.
Alto, listed on the New York Stock Exchange under the ticker ANRO, experienced a 7% rise in its stock price during premarket trading, reflecting positive investor sentiment regarding its research and development efforts in the neuropsychiatric space.